Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00049686 · ClinicalTrials.gov registry record · Phase 1
VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome
A Phase 1 study, sponsored by Vion Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00049686 is a Phase 1 study that has completed, run by Vion Pharmaceuticals.
The verdict
NCT00049686, a Phase 1 study, has completed, sponsored by Vion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of VNP40101M in treating patients who have relapsed or refractory leukemia or myelodysplastic syndrome.
Interventions
- DRUG laromustine
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-04 |
| Est. Completion | 2008-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00049686
The ClinicalTrials.gov registry entry for NCT00049686 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Vion Pharmaceuticals, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which laromustine is the first listed.
NCT00049686 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00049686 about?
NCT00049686 is a clinical study titled "VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of VNP40101M in treating patients who have relapsed or refractory leukemia or myelodysplastic syndrome.
What is the current status of trial NCT00049686?
This trial is currently completed. It is a Phase 1 study. The study started on 2002-04. Estimated completion is 2008-01.
What interventions are being tested in trial NCT00049686?
The interventions under investigation include: laromustine (DRUG).
Who is sponsoring clinical trial NCT00049686?
This trial is sponsored by Vion Pharmaceuticals, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.